Halozyme Therapeutics and Incyte entered a global collaboration and license agreement on July 20, 2026, granting Incyte rights to the ENHANZE drug delivery technology for subcutaneous formulations of INCA033989, per Halozyme's second-quarter report filed with the SEC. Incyte agreed to an upfront payment plus potential milestone payments and royalties on net sales; the amounts were not yet disclosed.
What are the terms of the deal?
Per the 8-K exhibit covering Halozyme's record second quarter, the agreement covers evaluation of additional subcutaneous formulations of INCA033989 — described by the company as a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody in patients with mutCALR-expressing myeloproliferative neoplasms — using Halozyme's proprietary ENHANZE technology, its recombinant human hyaluronidase platform that enables rapid, high-volume subcutaneous injection. Incyte also holds an option to nominate up to two additional targets for use with ENHANZE.
Under the terms, per the filing, Incyte agreed to make an upfront payment and potential future milestone payments and royalties on net sales of products developed with the technology. The specific upfront figure, milestone schedule and royalty rate were not yet disclosed. The deal was one of five new ENHANZE and Hypercon collaborations Halozyme signed through July 2026, alongside agreements with Vertex, Oruka, GSK and an undisclosed nucleic-acid-therapeutic partner.
What is INCA033989 and where does it stand?
INCA033989 is Incyte's antibody program against mutant calreticulin, a driver mutation in a subset of myeloproliferative neoplasms including essential thrombocythemia and myelofibrosis. Per Incyte's second-quarter report, the registrational Phase 3 study EXCALIBUR-ET2, evaluating INCA033989 in mutCALR-positive patients with ET who are resistant or intolerant to at least one prior cytoreductive therapy, was initiated in mid-2026. Updated Phase 1 data presented at the 2026 EHA Congress showed, in the company's characterization, robust clinical activity and durable hematologic and symptom responses in mutCALR-positive ET and MF patients.
What is the subcutaneous trial evidence so far?
No clinical results from any ENHANZE-formulated version of INCA033989 have been disclosed. The registry record for NCT07448155 describes a Phase 1, single-dose, open-label, parallel study of the pharmacokinetics, safety and tolerability of INCA033989 following subcutaneous or intravenous administration in healthy adult participants — with an actual start date of March 19, 2026, estimated enrollment of 126 participants and recruiting status as of July 2026. Incyte's report additionally states that a Phase 1 study evaluating subcutaneous administration in mutCALR-positive patients was initiated in the second quarter of 2026.
| Study | Design | Population | Status per source |
|---|---|---|---|
| NCT07448155 | Phase 1, single dose, open-label, SC vs IV | Healthy adults, 126 estimated | Recruiting; started March 19, 2026 |
| SC Phase 1 in patients | Phase 1, subcutaneous | mutCALR-positive patients | Initiated Q2 2026, per Incyte |
| EXCALIBUR-ET2 | Registrational Phase 3 | mutCALR-positive ET, resistant/intolerant to cytoreductive therapy | Initiated mid-2026, per Incyte |
Why does the deal matter?
For Incyte, the bet is that a subcutaneous formulation of a chronic-therapy antibody improves convenience enough to matter in a competitive MPN landscape. For Halozyme, the agreement extends a licensing model in which each new target nomination carries an upfront, milestones and royalties — a structure documented across its partner base, per the company's quarterly disclosure. Whether subcutaneous INCA033989 reaches patients will be decided by the Phase 1 formulation work and the EXCALIBUR-ET2 readout, for which no dates have been announced beyond trial initiation, per Incyte's filing.
This article is industry news coverage and is not medical advice. It does not assess the safety or efficacy of any investigational therapy.
